View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 22, 2021

Ampio obtains DCGI approval for Phase II Covid-19 trial of inhaled drug

In the trial, inhaled Ampion will be used to treat patients with respiratory distress associated with Covid-19.

Ampio Pharmaceuticals has obtained regulatory approval from the Drugs Controller General of India (DCGI) of the Central Drugs Standard Control Organization (CDSCO) to commence the Phase II AP-019 clinical trial of inhaled Ampion in the country.

A lead drug of Ampio, Ampion is an immunomodulatory agent possessing anti-inflammatory effects.

It disrupts the hyperactive immune response linked to Covid-19 and can potentially boost the clinical outcome in patients suffering from its complications.

The inhaled administration of Ampion aids the drug to directly target and reduce inflammation in the lungs, Ampio noted.

It will be used in the double-blind, placebo-controlled Phase II trial to treat individuals with Covid-19-associated respiratory distress.

The move comes after the Subject Expert Committee (SEC) established by the DCGI approved the AP-019 treatment protocol without recommending changes, Ampion noted.

Ampio president and CEO Mike Macaluso said: “More than a year and a half into the pandemic, healthcare practitioners still lack effective and easy-to-use therapies to treat the severe and often fatal respiratory distress experienced by many Covid-19 patients.

“We are grateful for the DCGI’s swift attention and believe their decision underscores the critical medical need for Ampion as a potential treatment option.”

The commencement of the Phase II trial of inhaled Ampion follows robust strong top-line data obtained from its Phase I AP-014 trial.

In April 2021, the company reported that the Phase I trial failed to meet its primary goal of safety and tolerability.

However, according to the top-line results, the drug was demonstrated to reduce all-cause mortality in Covid-19 respiratory distress by 78% as against the standard of care (SOC) for subjects with Covid-19-linked respiratory distress.

Furthermore, only 5% mortality was observed in subjects receiving SOC plus Ampion versus 24% in the SOC arm.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy